Research ArticleArticle
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
William Stohl, Joan T. Merrill, James D. McKay, Jeffrey R. Lisse, Z. John Zhong, William W. Freimuth and Mark C. Genovese
The Journal of Rheumatology April 2013, jrheum.120886; DOI: https://doi.org/10.3899/jrheum.120886
William Stohl
From the Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City; Division of Rheumatology and Immunology, Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; Section of Adult Rheumatology, Arizona Arthritis Center, University of Arizona, Tucson, Arizona; Human Genome Sciences Inc., Rockville, Maryland; and Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, California, USA. Supported by Human Genome Sciences (HGS), Rockville, Maryland, USA, and in part by US National Institutes of Health grant M01 RR-00043 to the General Clinical Research Center at the University of Southern California Keck School of Medicine. Dr. Merrill has received consultancy fees, speaking fees, and/or honoraria from HGS. Dr. McKay owns stock in HGS. Drs. Zhong and Freimuth are employed by and own stock in HGS. W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; J.T. Merrill, MD, Oklahoma Medical Research Foundation; J.D. McKay, DO, Oklahoma Center for Arthritis Therapy and Research; J.R. Lisse, MD, Arizona Arthritis Center, University of Arizona; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, HGS; M.C. Genovese, MD, Stanford School of Medicine. Address correspondence to Dr. W. Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Ave., HMR 711 Los Angeles, CA 90033, USA. E-mail: stohl@usc.edu Accepted for publication January 30, 2013.
Joan T. Merrill
From the Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City; Division of Rheumatology and Immunology, Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; Section of Adult Rheumatology, Arizona Arthritis Center, University of Arizona, Tucson, Arizona; Human Genome Sciences Inc., Rockville, Maryland; and Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, California, USA. Supported by Human Genome Sciences (HGS), Rockville, Maryland, USA, and in part by US National Institutes of Health grant M01 RR-00043 to the General Clinical Research Center at the University of Southern California Keck School of Medicine. Dr. Merrill has received consultancy fees, speaking fees, and/or honoraria from HGS. Dr. McKay owns stock in HGS. Drs. Zhong and Freimuth are employed by and own stock in HGS. W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; J.T. Merrill, MD, Oklahoma Medical Research Foundation; J.D. McKay, DO, Oklahoma Center for Arthritis Therapy and Research; J.R. Lisse, MD, Arizona Arthritis Center, University of Arizona; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, HGS; M.C. Genovese, MD, Stanford School of Medicine. Address correspondence to Dr. W. Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Ave., HMR 711 Los Angeles, CA 90033, USA. E-mail: stohl@usc.edu Accepted for publication January 30, 2013.
James D. McKay
From the Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City; Division of Rheumatology and Immunology, Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; Section of Adult Rheumatology, Arizona Arthritis Center, University of Arizona, Tucson, Arizona; Human Genome Sciences Inc., Rockville, Maryland; and Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, California, USA. Supported by Human Genome Sciences (HGS), Rockville, Maryland, USA, and in part by US National Institutes of Health grant M01 RR-00043 to the General Clinical Research Center at the University of Southern California Keck School of Medicine. Dr. Merrill has received consultancy fees, speaking fees, and/or honoraria from HGS. Dr. McKay owns stock in HGS. Drs. Zhong and Freimuth are employed by and own stock in HGS. W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; J.T. Merrill, MD, Oklahoma Medical Research Foundation; J.D. McKay, DO, Oklahoma Center for Arthritis Therapy and Research; J.R. Lisse, MD, Arizona Arthritis Center, University of Arizona; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, HGS; M.C. Genovese, MD, Stanford School of Medicine. Address correspondence to Dr. W. Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Ave., HMR 711 Los Angeles, CA 90033, USA. E-mail: stohl@usc.edu Accepted for publication January 30, 2013.
Jeffrey R. Lisse
From the Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City; Division of Rheumatology and Immunology, Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; Section of Adult Rheumatology, Arizona Arthritis Center, University of Arizona, Tucson, Arizona; Human Genome Sciences Inc., Rockville, Maryland; and Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, California, USA. Supported by Human Genome Sciences (HGS), Rockville, Maryland, USA, and in part by US National Institutes of Health grant M01 RR-00043 to the General Clinical Research Center at the University of Southern California Keck School of Medicine. Dr. Merrill has received consultancy fees, speaking fees, and/or honoraria from HGS. Dr. McKay owns stock in HGS. Drs. Zhong and Freimuth are employed by and own stock in HGS. W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; J.T. Merrill, MD, Oklahoma Medical Research Foundation; J.D. McKay, DO, Oklahoma Center for Arthritis Therapy and Research; J.R. Lisse, MD, Arizona Arthritis Center, University of Arizona; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, HGS; M.C. Genovese, MD, Stanford School of Medicine. Address correspondence to Dr. W. Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Ave., HMR 711 Los Angeles, CA 90033, USA. E-mail: stohl@usc.edu Accepted for publication January 30, 2013.
Z. John Zhong
From the Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City; Division of Rheumatology and Immunology, Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; Section of Adult Rheumatology, Arizona Arthritis Center, University of Arizona, Tucson, Arizona; Human Genome Sciences Inc., Rockville, Maryland; and Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, California, USA. Supported by Human Genome Sciences (HGS), Rockville, Maryland, USA, and in part by US National Institutes of Health grant M01 RR-00043 to the General Clinical Research Center at the University of Southern California Keck School of Medicine. Dr. Merrill has received consultancy fees, speaking fees, and/or honoraria from HGS. Dr. McKay owns stock in HGS. Drs. Zhong and Freimuth are employed by and own stock in HGS. W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; J.T. Merrill, MD, Oklahoma Medical Research Foundation; J.D. McKay, DO, Oklahoma Center for Arthritis Therapy and Research; J.R. Lisse, MD, Arizona Arthritis Center, University of Arizona; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, HGS; M.C. Genovese, MD, Stanford School of Medicine. Address correspondence to Dr. W. Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Ave., HMR 711 Los Angeles, CA 90033, USA. E-mail: stohl@usc.edu Accepted for publication January 30, 2013.
William W. Freimuth
From the Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City; Division of Rheumatology and Immunology, Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; Section of Adult Rheumatology, Arizona Arthritis Center, University of Arizona, Tucson, Arizona; Human Genome Sciences Inc., Rockville, Maryland; and Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, California, USA. Supported by Human Genome Sciences (HGS), Rockville, Maryland, USA, and in part by US National Institutes of Health grant M01 RR-00043 to the General Clinical Research Center at the University of Southern California Keck School of Medicine. Dr. Merrill has received consultancy fees, speaking fees, and/or honoraria from HGS. Dr. McKay owns stock in HGS. Drs. Zhong and Freimuth are employed by and own stock in HGS. W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; J.T. Merrill, MD, Oklahoma Medical Research Foundation; J.D. McKay, DO, Oklahoma Center for Arthritis Therapy and Research; J.R. Lisse, MD, Arizona Arthritis Center, University of Arizona; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, HGS; M.C. Genovese, MD, Stanford School of Medicine. Address correspondence to Dr. W. Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Ave., HMR 711 Los Angeles, CA 90033, USA. E-mail: stohl@usc.edu Accepted for publication January 30, 2013.
Mark C. Genovese
From the Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City; Division of Rheumatology and Immunology, Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; Section of Adult Rheumatology, Arizona Arthritis Center, University of Arizona, Tucson, Arizona; Human Genome Sciences Inc., Rockville, Maryland; and Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, California, USA. Supported by Human Genome Sciences (HGS), Rockville, Maryland, USA, and in part by US National Institutes of Health grant M01 RR-00043 to the General Clinical Research Center at the University of Southern California Keck School of Medicine. Dr. Merrill has received consultancy fees, speaking fees, and/or honoraria from HGS. Dr. McKay owns stock in HGS. Drs. Zhong and Freimuth are employed by and own stock in HGS. W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; J.T. Merrill, MD, Oklahoma Medical Research Foundation; J.D. McKay, DO, Oklahoma Center for Arthritis Therapy and Research; J.R. Lisse, MD, Arizona Arthritis Center, University of Arizona; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, HGS; M.C. Genovese, MD, Stanford School of Medicine. Address correspondence to Dr. W. Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Ave., HMR 711 Los Angeles, CA 90033, USA. E-mail: stohl@usc.edu Accepted for publication January 30, 2013.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
William Stohl, Joan T. Merrill, James D. McKay, Jeffrey R. Lisse, Z. John Zhong, William W. Freimuth, Mark C. Genovese
The Journal of Rheumatology Apr 2013, jrheum.120886; DOI: 10.3899/jrheum.120886
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
William Stohl, Joan T. Merrill, James D. McKay, Jeffrey R. Lisse, Z. John Zhong, William W. Freimuth, Mark C. Genovese
The Journal of Rheumatology Apr 2013, jrheum.120886; DOI: 10.3899/jrheum.120886